{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:51:46Z","timestamp":1774644706961,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s11940-019-0545-6","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T22:39:52Z","timestamp":1548715192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Advances in Management of Psychosis in Neurodegenerative Diseases"],"prefix":"10.1007","volume":"21","author":[{"given":"Kasia Gustaw","family":"Rothenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Rajaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"545_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: APA; 2013.","edition":"5"},{"issue":"3","key":"545_CR2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0019-5545.224475","volume":"60","author":"S Gautam","year":"2018","unstructured":"Gautam S, Jain A, Gautam M, Gautam A. Clinical practice guideline for management of psychoses in elderly. Indian J Psychiatry. 2018;60(3):363\u201370.","journal-title":"Indian J Psychiatry"},{"issue":"3","key":"545_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jagp.2012.12.211","volume":"21","author":"A Javadpou","year":"2013","unstructured":"Javadpou A, Sehatpour M, Mani A, Sahraian A. Assessing diagnosis and symptoms profile of late life psychosis among an elderly population. Am J Geriatr Psychiatr. 2013;21(3):159\u201360.","journal-title":"Am J Geriatr Psychiatr"},{"issue":"11","key":"545_CR4","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1176\/appi.ajp.162.11.2022","volume":"162","author":"SA Ropacki","year":"2005","unstructured":"Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer\u2019s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatr. 2005;162(11):2022\u201330.","journal-title":"Am J Psychiatr"},{"issue":"1","key":"545_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/0891988706292762","volume":"20","author":"Sytse Zuidema","year":"2007","unstructured":"Zuidema S, Koopmans R, Verhey F. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. J Geriatr Psychiatry Neurol. 2007 Mar;20(1):41\u20139.","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"545_CR6","doi-asserted-by":"crossref","unstructured":"Rothenberg KG. Assessment and Management of Psychiatric Symptoms in Neurodegenerative Disorders (Chapter 23) In: Neuro-Geriatrics (Ed.) Tousi Babak and Cummings Jeffrey 2017, Springer International Publishing AG. * (Comprehensive review of treatment of NPS in NDD).","DOI":"10.1007\/978-3-319-56484-5_23"},{"key":"545_CR7","doi-asserted-by":"publisher","unstructured":"APA Practice Guideline Writing Group\u2019s \u201cPractice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. https:\/\/doi.org\/10.1176\/appi.books.9780890426807 .","DOI":"10.1176\/appi.books.9780890426807"},{"issue":"9916","key":"545_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"\u2022\u2022 Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340 This Paper summarizes pharmacological properties of pimavanserin and results which led to its approval by FDA.","journal-title":"Lancet"},{"issue":"9","key":"545_CR9","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1176\/appi.ajp.2012.11101529","volume":"169","author":"H Brodaty","year":"2012","unstructured":"Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946\u201353.","journal-title":"Am J Psychiatry"},{"key":"545_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1192\/bjp.157.1.72","volume":"157","author":"A Burns","year":"1990","unstructured":"Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer\u2019s disease. Parts I-IV. Br J Psychiatry. 1990;157:72\u201394.","journal-title":"Br J Psychiatry"},{"issue":"7","key":"545_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3928\/00485713-20150626-06","volume":"45","author":"KG Rothenberg","year":"2015","unstructured":"Rothenberg KG, Wiechers IR. Antipsychotics for neuropsychiatric symptoms of dementia\u2014safety and efficacy in the context of informed consent. Psychiatr Ann. 2015;45(7):348\u201353.","journal-title":"Psychiatr Ann"},{"issue":"9","key":"545_CR12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1176\/appi.ajp.2013.12081046","volume":"170","author":"OL Lopez","year":"2013","unstructured":"Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, Snitz B, et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer\u2019s disease. Am J Psychiatry. 2013;170(9):1051\u20138.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"545_CR13","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1212\/WNL.54.10.1965","volume":"54","author":"JS Paulsen","year":"2000","unstructured":"Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, et al. Incidence of and risk factors for psychosis of Alzheimer\u2019s disease. Neurology. 2000;54(10):1965\u201371.","journal-title":"Neurology"},{"issue":"2","key":"545_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1017\/S1041610209991001","volume":"22","author":"PA Wilkosz","year":"2010","unstructured":"Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, DeKosky ST, et al. Trajectories of cognitive decline in Alzheimer\u2019s disease. Int Psychogeriatr. 2010;22(2):281\u201390.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"545_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00019442-200002000-00004","volume":"8","author":"D Jeste","year":"2000","unstructured":"Jeste D, Finkel S. Psychosis of Alzheimer\u2019s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatr. 2000;8(1):29\u201334.","journal-title":"Am J Geriatr Psychiatr"},{"issue":"2","key":"545_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3233\/JAD-150944","volume":"51","author":"G D'Onofrio","year":"2016","unstructured":"D'Onofrio G, Panza F, Sancarlo D, Paris FF, Cascavilla L, Mangiacotti A, et al. Delusions in patients with Alzheimer\u2019s disease: a multidimensional approach. J Alzheimers Dis. 2016;51(2):427\u201337.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"545_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.410400309","volume":"40","author":"DE Kuhl","year":"1996","unstructured":"Kuhl DE, Minoshima S, Fessler JA, Ficaro EP, Wieland DM, Koeppe RA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer\u2019s disease, and Parkinson\u2019s disease. Ann Neurol. 1996;40(3):399\u2013410.","journal-title":"Ann Neurol"},{"issue":"9","key":"545_CR18","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.neurobiolaging.2014.03.003","volume":"35","author":"Jeremy Koppel","year":"2014","unstructured":"Koppel J, Acker C, Davies P, Lopez OL, Jimenez H, Azose M, et al. Psychotic Alzheimer\u2019s disease is associated with gender-specific tau phosphorylation abnormalities. Neurobiol Aging. 2014 Sep;35(9):2021\u20138.","journal-title":"Neurobiology of Aging"},{"issue":"9","key":"545_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.parkreldis.2014.06.018","volume":"20","author":"Sandra A. Jacobson","year":"2014","unstructured":"Jacobson SA, Morshed T, Dugger BN, Beach TG, Hentz JG, Adler CH, et al. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord. 2014 Sep;20(9):1009\u201314.","journal-title":"Parkinsonism & Related Disorders"},{"key":"545_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/01.JGP.0000221293.91312.d3","volume":"14","author":"JL Cummings","year":"2006","unstructured":"Cummings JL, McRae T, Zhang R, The Donepezil-Sertraline Study Group. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14:605\u201311.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"545_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cns.12484","volume":"22","author":"Jeffrey Cummings","year":"2016","unstructured":"Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, et al. Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer\u2019s disease and dementia with Lewy bodies. CNS Neurosci Ther. 2016 Mar;22(3):159\u201366.","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"Suppl1","key":"545_CR22","first-page":"1","volume":"5","author":"N Herrmann","year":"2013","unstructured":"Herrmann N, Lanct\u00f4t KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5(Suppl1):1\u201312.","journal-title":"Alzheimers Res Ther"},{"key":"545_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","volume":"63","author":"C Holmes","year":"2004","unstructured":"Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214\u20139.","journal-title":"Neurology"},{"issue":"3","key":"545_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4088\/JCP.v69n0302","volume":"69","author":"GK Wilcock","year":"2008","unstructured":"Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation\/aggression and psychosis in moderately severe to severe Alzheimer\u2019s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341\u20138.","journal-title":"J Clin Psychiatry"},{"key":"545_CR25","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","volume":"367","author":"DP Devanand","year":"2012","unstructured":"Devanand DP, Mintzer J, Schultz SK. Relapse risk after discontinuation of risperidone in Alzheimer\u2019s disease. N Engl J Med. 2012;367:1497\u2013507.","journal-title":"N Engl J Med"},{"key":"545_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/153331750301800410","volume":"18","author":"R Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer\u2019s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205\u201314.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"11","key":"545_CR27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","volume":"15","author":"Jacobo E. Mintzer","year":"2007","unstructured":"Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov;15(11):918\u201331.","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"5","key":"545_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/gps.1792","volume":"22","author":"Ira Katz","year":"2007","unstructured":"Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer\u2019s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May;22(5):475\u201384.","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"10","key":"545_CR29","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","volume":"57","author":"JS Street","year":"2000","unstructured":"Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000;57(10):968\u201376.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"545_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jcpt.12357","volume":"41","author":"N. El-Saifi","year":"2016","unstructured":"El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther. 2016 Feb;41(1):7\u201318.","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"9","key":"545_CR31","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.4088\/JCP.17m11461","volume":"78","author":"C Ozawa","year":"2017","unstructured":"Ozawa C, Roberts R, Yoshida K, Suzuki T, Lebowitz B, Reeves S, et al. Placebo effects in the treatment of noncognitive symptoms of Alzheimer\u2019s disease: analysis of the CATIE-AD data. J Clin Psychiatry. 2017;78(9):1204\u201310.","journal-title":"J Clin Psychiatry"},{"issue":"32","key":"545_CR32","first-page":"63","volume":"293-300","author":"L Marsh","year":"2004","unstructured":"Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;293-300(32):63.","journal-title":"Neurology"},{"key":"545_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","volume":"289","author":"G Fenelon","year":"2010","unstructured":"Fenelon G, Alves G. Epidemiology of psychosis in Parkinson\u2019s disease. J Neurol Sci. 2010;289:12\u20137.","journal-title":"J Neurol Sci"},{"key":"545_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/mds.22839","volume":"25","author":"G Fenelon","year":"2010","unstructured":"Fenelon G, Soulas T, Zenasni F, de Langavant LC. The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25:755\u20139.","journal-title":"Mov Disord"},{"key":"545_CR35","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"B Ravina","year":"2007","unstructured":"Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061\u20138.","journal-title":"Mov Disord"},{"issue":"Pt 4","key":"545_CR36","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G Fenelon","year":"2000","unstructured":"Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733\u201345.","journal-title":"Brain"},{"issue":"11","key":"545_CR37","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/mds.22132","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson\u2019s disease: positive impact on long-term worsening. Mov Disord. 2008;23(11):1541\u20135.","journal-title":"Mov Disord"},{"key":"545_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1176\/jnp.13.2.222","volume":"13","author":"T Murai","year":"2001","unstructured":"Murai T, Muller U, Werheid K, et al. In vivo evidence for differential association of striatal dopamine and midbrainserotonin systems with neuropsychiatric symptoms in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci. 2001;13:222\u20138.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"545_CR39","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/mds.23083","volume":"25","author":"P Huot","year":"2010","unstructured":"Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord. 2010;25:1399\u2013408.","journal-title":"Mov Disord"},{"issue":"pt 2","key":"545_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/brain\/awf033","volume":"125","author":"AJ Harding","year":"2002","unstructured":"Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(pt 2):391\u2013403.","journal-title":"Brain"},{"issue":"3","key":"545_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11940-013-0281-2","volume":"16","author":"JG Goldman","year":"2014","unstructured":"Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson\u2019s disease. Curr Treat Options Neurol. 2014;16(3):281\u201399.","journal-title":"Curr Treat Options Neurol"},{"key":"545_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/153331750301800410","volume":"18","author":"R Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer\u2019s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205\u201314.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"545_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1176\/jnp.9.4.594","volume":"9","author":"RH Workman Jr","year":"1997","unstructured":"Workman RH Jr, Orengo CA, Bakey AA, et al. The use of risperidonefor psychosis and agitation in demented patients with Parkinson disease. J Neuropsychiatry Clin Neurosci. 1997;9:594\u20137.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"5","key":"545_CR44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, Dest\u00e9e A, P\u00e9r\u00e9 JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"545_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","volume":"27","author":"L Morgante","year":"2004","unstructured":"Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27(4):153\u20136.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"545_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/0891988716640378","volume":"29","author":"Philippe Desmarais","year":"2016","unstructured":"Desmarais P, Massoud F, Filion J, Nguyen QD, Bajsarowicz P. Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders: a systematic review. J Geriatr Psychiatry Neurol. 2016;29(4):227\u201336 Systematic review of effectiveness of quetiapine in PD psychosis.","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"545_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4088\/JCP.10m05973gry","volume":"72","author":"L Hausner","year":"2011","unstructured":"Hausner L, Damian M, Sartorius A, Frolich L. Efficacy and cognitive side effects of ECT in depressed elderly inpatients with co-existing mild cognitive impairment or dementia. J Clin Psychiatry. 2011;72:91\u20137.","journal-title":"J Clin Psychiatry"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-019-0545-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0545-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0545-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T02:00:51Z","timestamp":1662861651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-019-0545-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1007\/s11940-019-0545-6","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"23 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"3"}}